- Sep 30, 2022
NCT05561387: Phase 3: Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma NDMM
- Sep 28, 2022
NCT05558319: Phase 3: (GEM21menos65) Extended VRD Plus vs Isa-VRD vs Isa-V-Iberdomide - NDMM - ASCT
- Sep 27, 2022
NCT05556616: Phase 1: A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma
- Sep 23, 2022
NCT05552976: Phase 3: CC-92480 + Carfilzomib-dex (480Kd) Vs Carfilzomib-dex (Kd) RRMM (SUCCESSOR-2)
- Sep 23, 2022
NCT05552222: Phase 3: Teclistamab-Daratumumab-Len (Tec-DR) Vs Dara-Len-dex (DRd) (MajesTEC-7) NDMM
- Sep 19, 2022
NCT05463939: Teclistamab Expanded Access Treatment Protocol for Relapsed or Refractory Myeloma
- Sep 16, 2022
HealthTree Myeloma Round Table in Buffalo on September 17, 2022 / 09:00AM - 03:00PM EDT
- Sep 14, 2022
SCIP & SAVOR FOR A CURE - A Fundraising Hosted By: Fatima and Jimmy Scipione - Sat Oct 15th, 2022
- Sep 1, 2022
#IMS2022 - 19th International Myeloma Society Annual Meeting; Aug 25-27, LA California
- Sep 1, 2022
NCT05509530: Phase 2: Safety and Efficacy of Anti-BCMA/GPRC5D CAR-T Cell Therapy in Treating RRMM
- Sep 1, 2022
NCT05455320: Phase 3 - (Talquetamab) Tal-DP Vs Tal-D Vs DPd - RRMM -Multiple Myeloma (MonumenTAL-3)
- Sep 1, 2022
NCT05519085: Phase 3: CC-92480 + Bortezomib-dex (480Vd) Vs Pom-Bortzomib-dex (PVd) RRMM -SUCCESSOR-1
- Sep 1, 2022
NCT05427812: Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma
- Sep 1, 2022
NCT05461209: Phase 3: Talquetamab Vs Belantamab Mafodotin RRMM - (MonumenTAL-5)